ARTICLE | Company News
Merck, Bionomics deal
June 30, 2014 7:00 AM UTC
Bionomics granted Merck exclusive, worldwide development and commercialization rights to Bionomics’ preclinical BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease...